The Food and Drug Administration Friday authorized the first prescription diagnostic test for both COVID-19 and influenza A and B that allows patients to collect a sample at home and ship it to a laboratory for analysis.

The Quest Diagnostics test received emergency use authorization for use by individuals with a suspected respiratory viral infection consistent with COVID-19 when their health care provider deems home collection appropriate.

“With just one swab or sample, combination tests that are authorized for use with home-collected samples can be used to get answers to Americans faster, in the comfort and relative safety of their home, which allows patients to continue to quarantine while awaiting results,” said FDA Commissioner Stephen Hahn, M.D.

Related News Articles

Blog
The Centers for Medicare & Medicaid Services recently announced that Medicare will not continue to cover audio-only telehealth visits when the COVID-19…
Headline
In this AHA video for Mother’s Day, part of AHA’s #MyWhy social media campaign, a pregnant health care worker explains why she chose to get…
Headline
Moderna Inc. told investors today that is intends to soon file for full Food and Drug Administration approval for its COVID-19 vaccine. Moderna, whose…
Headline
AHA yesterday urged the Department of Health and Human Services to extend the deadline for hospitals and other health care providers to use their COVID-19…
Blog
In this update to his September 2020 blog post, Mike Schiller, senior director of supply chain for the AHA’s Association for Health Care Resource and Materials…
Headline
The AHA today donated to UNICEF to help hospitals and communities fight a devastating surge in COVID-19 cases in India. UNICEF is rushing urgently needed…